Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Amgen 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Amgen 3Q

Product sales fell 1% in 3Q09 to $3.7 billion; U.S. sales were flat at $2.9 billion.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen 3Q09

3Q Revenues: $3.8 billion (flat)

3Q Earnings: $1.4 billion (+23%)

YTD Revenues: $10.8 billion (-4%)

YTD Earnings: $3.7 billion (+17%)

Comments: Product sales fell 1% in 3Q09 to $3.7 billion; U.S. sales were flat at $2.9 billion. Enbrel sales climbed 3% to $924 million, with a price increase offsetting a drop in unit sales in dermatology. Aranesp sales fell 19% to $685 million in the quarter, while Epogen rose 5% to $663 million. Neulasta and Neupogen sales grew 2% to $1.2 billion. For YTD, Enbrel sales are -4% at $2.6 billion.

Read Amgen’s profile in this year’s Top 10 Biopharmas Report!

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters